Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Translating microbiome futures

This article has been updated

A group of microbiome researchers discuss some of the challenges in developing a new generation of microbiome therapies.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Over the past five years, the scientific output in the microbiome field and the number of microbiome-related published patents has been steadily rising.
Figure 2: The microbiome investment landscape.
Figure 3: New microbiome-related companies have been steadily founded, and the number of partnerships in the field has grown exponentially.

Change history

  • 19 November 2018

    In the HTML version of this article initially published online, Box 1 was missing. The error has been corrected online as of 19 November 2018.


  1. Fankhauser, M., Moser, C. & Nyfeler, T. Patents as early indicators of technology and investment trends: analyzing the microbiome space as a case study. Front. Bioeng. Biotechnol. 6, 84 (2018).

    Article  Google Scholar 

  2. University of Chicago Technology Commercialization. Polsky Microbiome – Venture Funding Data. (2018).

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Gaspar Taroncher-Oldenburg.

Ethics declarations

Competing interests

G.T.-O. is consultant-in-residence at Global Engage and became an advisor to the Janssen Human Microbiome Institute after completion of Microbiome Futures; M.B. serves on the scientific advisory boards of Elysium, Inc, Ubiome, Inc., Commense, Inc. and Seed, Inc.; R.B. has served as an expert witness for Kirkland and Ellis LLC, in advisory and consulting roles to the Simons Foundation, Novartis, Eli Lilly and Merus, and is currently collaborating with Novartis and Merus; P.C. is CEO and Co-Founder of General Automation Lab Technologies, Inc.; E.E. is a scientific consultant to DayTwo & BiomX; C.H. serves on the scientific advisory boards of Seres Therapeutics and Microbiome Insights; D. Kyle is an employee of, and owns shares in, Evolve BioSystems Inc.; D.L. is founder of and advisor to Vedanta, Director at Pfizer, Inc., and a recipient of research funding for microbiota projects from Boehringer Ingelheim; A. Maiti is an employee of Pfizer Inc.; A. Maue is an employee of Taconic Biosciences; B.O. is an employee of Vedanta Biosciences, a company developing drugs in the human microbiome field, and holds stock options in the company; J.E.T.v.H.V. is an employee of Chr. Hansen A/S; J.W. is founder & CEO of iCarbonX.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Taroncher-Oldenburg, G., Jones, S., Blaser, M. et al. Translating microbiome futures. Nat Biotechnol 36, 1037–1042 (2018).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing